Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Fallopian Tube Cancer Clinical Trials

10 recruiting trials for Fallopian Tube Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
2
Phase 3 Trials
9
Sponsors

Recruiting Trials

RECRUITINGPhase 2NCT05200260

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

Sponsor: Shanghai Gynecologic Oncology GroupEnrolling: 2209 locations
RECRUITINGNCT05912972

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer...

Sponsor: Asan Medical CenterEnrolling: 135001 location
RECRUITINGNCT05574673

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of...

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials UnitEnrolling: 10001 location
RECRUITINGNCT05236686

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian...

Sponsor: Shanghai Gynecologic Oncology GroupEnrolling: 941 location
RECRUITINGPhase 3NCT06915025

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant...

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: ImunonEnrolling: 5007 locations
RECRUITINGNCT05287451

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High...

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1009 locations
RECRUITINGPhase 2NCT06787612

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of...

Sponsor: Regeneron PharmaceuticalsEnrolling: 22020 locations
RECRUITINGPhase 3NCT05009082

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and...

Sponsor: AGO Study GroupEnrolling: 97020 locations
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations
RECRUITINGPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid...

Sponsor: GenmabEnrolling: 76420 locations